Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SEC Investigating Cassava Sciences: DJ

11/17/2021 | 09:05am EST


ę MT Newswires 2021
All news about CASSAVA SCIENCES, INC.
01/12SOCIAL BUZZ : Wallstreetbets Stocks Mixed Premarket Wednesday
MT
01/06CASSAVA SCIENCES INC : Change in Directors or Principal Officers, Financial Statements and..
AQ
01/06SOCIAL BUZZ : Wallstreetbets Stocks Gets Spooked by Hawkish Fed; Shares Mostly Lower Pre-B..
MT
2021Cassava Sciences Launches Website to Back Phase 3 Studies of Simufilam for Alzheimer's ..
MT
2021Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam..
MT
2021Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam..
GL
2021Cassava Sciences, Inc. - Science Journal Finds No Evidence to Support Claims of Data Ma..
AQ
2021SOCIAL BUZZ : Wallstreetbets Stocks Mostly Trade Higher; Cassava Jumps 21% After Journal F..
MT
2021Cassava Sciences Says Academic Journal Found No Evidence of Data Manipulation in 2005 P..
MT
2021Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Public..
GL
More news
Analyst Recommendations on CASSAVA SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -32,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -51,0x
Yield 2021 -
Capitalization 1 660 M 1 660 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 24,9x
Nbr of Employees 11
Free-Float -
Chart CASSAVA SCIENCES, INC.
Duration : Period :
Cassava Sciences, Inc. Technical Analysis Chart | SAVA | US14817C1071 | MarketScreener
Technical analysis trends CASSAVA SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 41,48 $
Average target price 140,67 $
Spread / Average Target 239%
EPS Revisions
Managers and Directors
Remi Barbier Chairman, President & Chief Executive Officer
Eric J. Schoen Chief Financial Officer
Nadav Friedmann Director, Chief Operating & Medical Officer
James W. Kupiec Chief Clinical Development Officer
Michael Zamloot Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CASSAVA SCIENCES, INC.-5.08%1 660
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-5.55%54 178
BIONTECH SE-34.36%40 873